PMGC Q3 10-Q: $10.2M Nine-Month Loss, Going Concern Doubt, $7.3M ELOC Convertible Debt
ELAB is trading near its 52-week low of $1.41 (12% above the low) on light trading volume (0.1× avg).
Summary
PMGC's Q3 10-Q reports a $10.2 million nine-month net loss, $7.2 million of operating cash burn, and renewed going-concern doubt, alongside $7.3 million of convertible ELOC debt that converts at a discount to market.
Key Events · Earnings and Guidance · ELAB
-
Nine-Month Loss Widens to $10.2M
Net loss for the nine months ended September 30, 2026 was $10,151,379 versus $4,765,130 a year earlier, on revenue of $4,518,968 versus $285,948.
-
Going Concern Doubt Reiterated
Accumulated deficit reached $31,332,382 and operating cash burn was $7,226,484; management cites substantial doubt about continuing as a going concern, with the $100,422,693 SPAC trust restricted and unavailable for operations.
-
$7.3M Convertible ELOC Debt Outstanding
Convertible debt under the First and Second ELOC agreements totaled $7,259,043 at September 30, 2026, after $27,620,768 of principal drawn in the period; conversion prices are 88% and 97% of the lowest VWAP over 10 and 5 trading days respectively.
-
Post-Quarter Share Issuance at $1.40-$2.25
Subsequent to quarter-end, 279,349 shares were issued between November 2 and November 9, 2026 at $1.40 to $2.25 per share to settle $561,500 of Pre-Paid Purchase #2, leaving roughly $529,523 outstanding.
Analysis · ELAB · Life Sciences
Cash is burning faster than it is being earned: a $10.2 million nine-month net loss against $4.5 million of revenue, and $7.2 million of operating cash burn. Management repeats that these conditions raise substantial doubt about the ability to continue as a going concern, and the balance sheet now carries $7.3 million of convertible debt tied to two equity line facilities whose conversion prices float at 88-97% of VWAP — a structure that converts lender draws into new shares at a discount. The $100 million SPAC trust is restricted and cannot fund operations. The offset is that revenue has scaled sharply from acquisitions (SVM, A&B Aerospace), but the precision machining segment's AGA unit runs a negative gross margin.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELAB was trading at $1.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $1.41 to $1,432.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.